[{"id":"2b3e863c-cc9b-4df3-83a2-6eecb5cf291b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04077866","created_at":"2021-01-18T19:58:10.932Z","updated_at":"2024-07-02T16:35:58.453Z","phase":"Phase 1/2","brief_title":"B7-H3 CAR-T for Recurrent or Refractory Glioblastoma","source_id_and_acronym":"NCT04077866","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • BP102"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2022-12-28"},{"id":"dc367bc1-2fb0-4ffe-9bd0-e5057ee3ca6e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04385173","created_at":"2021-01-18T21:10:18.596Z","updated_at":"2024-07-02T16:35:58.461Z","phase":"Phase 1","brief_title":"Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma","source_id_and_acronym":"NCT04385173","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Airuituo (bevacizumab biosimilar) • BP102"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2022-12-28"}]